 |
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Investors
SPARK Ventures is the leading quoted early-stage venture capital company in Europe. It manages over £200 million on behalf of major institutional investors, leading UK universities, and two quoted venture capital trusts. SPARK invests in entrepreneurs to create dynamic businesses in the technology, media, telecoms and healthcare & life sciences sectors. As well as capital, it brings a wealth of experience of developing high growth companies from early stage through to IPO or trade sale, adding value to its investments through active support and strategic direction.
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures’ portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
For further information, please visit: www.hbmbioventures.com
With close to €2Bn under management, AGF Private Equity, a member of the Allianz Group, is specialized in non -listed investments. Among the leading French funds, AGF Private Equity’s venture branch manages €300M, and has invested in more than 60 high tech companies. As one of the most active venture firms in Europe, AGF Private Equity is a strong partner of growth companies.
For further information, please visit www.agfpe.com
For further information, please visit: www.sparkventures.com
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures’ portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
For further information, please visit: www.hbmbioventures.com
With close to €2Bn under management, AGF Private Equity, a member of the Allianz Group, is specialized in non -listed investments. Among the leading French funds, AGF Private Equity’s venture branch manages €300M, and has invested in more than 60 high tech companies. As one of the most active venture firms in Europe, AGF Private Equity is a strong partner of growth companies.
For further information, please visit www.agfpe.com
Having closed Series A and B financing rounds successfully in 2006 and 2007 plus an interim round in 2009 Vivacta anticipate that future opportunities will arise at a later date.
Any interest to be contacted with regard to future investment should be through the Chief Executive: Tim Carter, email: tc@vivacta.com
Use of system
Vivacta's piezofilm detection system consists of a bench-top, portable reader and a single use, disposable cartridge, which acts as the whole blood collection device. For more information and to view the system in use Click here